^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Conmana (icotinib)

    i
    Company:
    Betta Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2) (NCT04401059)
    Phase 4
    Tian Xie
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    11/09/2020
    Primary completion :
    09/30/2025
    Completion :
    03/30/2026
    EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1
    |
    EGFR mutation • EGFR L858R • EGFR positive
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)
    Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation (NCT05263947)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    01/16/2023
    Initiation :
    08/30/2021
    Primary completion :
    10/30/2023
    Completion :
    12/30/2023
    EGFR
    |
    EGFR mutation • EGFR L858R
    |
    Avastin (bevacizumab) • Conmana (icotinib)
    A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection (NCT05514314)
    Phase 2
    Wu Nan
    Not yet recruiting
    Last update posted :
    08/24/2022
    Initiation :
    09/01/2022
    Primary completion :
    09/30/2024
    Completion :
    06/30/2025
    EGFR • KRAS
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    Icotinib for Completed Resected IB NSCLC With EGFR Mutation (CORIN) (NCT02264210)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    08/03/2021
    Initiation :
    01/01/2015
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (EVIDENCE) (NCT02448797)
    Phase 3
    Betta Pharmaceuticals Co., Ltd.
    Active, not recruiting
    Last update posted :
    07/20/2021
    Initiation :
    06/08/2015
    Primary completion :
    06/30/2022
    Completion :
    12/01/2023
    EGFR
    |
    EGFR mutation
    |
    cisplatin • pemetrexed • Conmana (icotinib) • vinorelbine tartrate
    Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT) (NCT04797806)
    Phase 3
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    03/15/2021
    Initiation :
    03/12/2021
    Primary completion :
    04/30/2022
    Completion :
    04/30/2023
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Focus V (anlotinib) • Conmana (icotinib)
    Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004) (NCT03736837)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Completed
    Last update posted :
    03/15/2021
    Initiation :
    12/01/2018
    Primary completion :
    01/01/2021
    Completion :
    01/01/2021
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Focus V (anlotinib) • Conmana (icotinib)
    Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation (NCT02737774)
    Phase 2
    Henan Cancer Hospital
    Unknown status
    Last update posted :
    07/01/2020
    Initiation :
    04/13/2016
    Primary completion :
    10/25/2019
    Completion :
    06/01/2021
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    carboplatin • pemetrexed • Conmana (icotinib)
    A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (SMART) (NCT04058704)
    Phase 3
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    08/15/2019
    Initiation :
    07/20/2018
    Primary completion :
    12/31/2022
    Completion :
    12/31/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Conmana (icotinib)
    Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH (NCT01855854)
    Phase 2
    Betta Pharmaceuticals Co., Ltd.
    Completed
    Last update posted :
    07/05/2019
    Initiation :
    05/01/2013
    Primary completion :
    08/01/2015
    Completion :
    01/07/2016
    EGFR
    |
    EGFR overexpression
    |
    Conmana (icotinib)
    Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (NCT01719536)
    Phase 3
    Betta Pharmaceuticals Co., Ltd.
    Completed
    Last update posted :
    07/05/2019
    Initiation :
    12/01/2012
    Primary completion :
    09/01/2016
    Completion :
    02/07/2017
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    cisplatin • pemetrexed • Conmana (icotinib)
    Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI (NCT04007835)
    Phase N/A
    Guangdong Association of Clinical Trials
    Unknown status
    Last update posted :
    07/05/2019
    Initiation :
    07/01/2019
    Primary completion :
    07/01/2021
    Completion :
    12/01/2021
    EGFR
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)
    Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. (NCT03992885)
    Phase 3
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    06/20/2019
    Initiation :
    07/01/2019
    Primary completion :
    07/01/2020
    Completion :
    08/01/2025
    EGFR
    |
    EGFR mutation
    |
    cisplatin • carboplatin • pemetrexed • Conmana (icotinib)
    High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases (NCT02726568)
    Phase 2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    02/19/2019
    Initiation :
    03/01/2016
    Primary completion :
    12/01/2021
    Completion :
    12/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Conmana (icotinib)
    Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer (NCT03766490)
    Phase N/A
    The First Affiliated Hospital of Soochow Univer...
    Unknown status
    Last update posted :
    01/30/2019
    Initiation :
    03/30/2019
    Primary completion :
    12/20/2019
    Completion :
    12/20/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib • Focus V (anlotinib) • Conmana (icotinib)
    Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer (NCT03749213)
    Phase 2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    11/21/2018
    Initiation :
    12/01/2018
    Primary completion :
    02/01/2022
    Completion :
    12/30/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC (secgolc004) (NCT03720873)
    Phase 2
    Fujian Cancer Hospital
    Unknown status
    Last update posted :
    10/25/2018
    Initiation :
    10/01/2018
    Primary completion :
    06/01/2021
    Completion :
    09/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation
    |
    erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)
    Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation (ICTAN) (NCT01996098)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    08/28/2018
    Initiation :
    01/01/2014
    Primary completion :
    01/01/2020
    Completion :
    01/01/2023
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer (NCT03396185)
    Phase 2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    07/18/2018
    Initiation :
    05/09/2018
    Primary completion :
    02/01/2022
    Completion :
    02/01/2023
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer (NCT03349203)
    Phase 2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    07/18/2018
    Initiation :
    10/01/2018
    Primary completion :
    02/01/2022
    Completion :
    12/30/2023
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP) (NCT02125240)
    Phase 3
    Betta Pharmaceuticals Co., Ltd.
    Unknown status
    Last update posted :
    07/16/2018
    Initiation :
    09/01/2014
    Primary completion :
    12/01/2018
    Completion :
    07/01/2021
    EGFR
    |
    EGFR mutation
    |
    cisplatin • Conmana (icotinib)
    Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation (NCT03151161)
    Phase 2
    Sun Yat-sen University
    Unknown status
    Last update posted :
    06/07/2018
    Initiation :
    12/01/2015
    Primary completion :
    12/31/2018
    Completion :
    05/01/2019
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    carboplatin • pemetrexed • Conmana (icotinib)
    Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma (NCT01534585)
    Phase 1/2
    Taizhou Hospital
    Completed
    Last update posted :
    04/17/2018
    Initiation :
    02/01/2012
    Primary completion :
    02/01/2013
    Completion :
    02/01/2015
    EGFR
    |
    cisplatin • paclitaxel • Conmana (icotinib)
    Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC (NCT03402464)
    Phase 2
    Peking University Cancer Hospital & Institute
    Unknown status
    Last update posted :
    01/18/2018
    Initiation :
    01/01/2018
    Primary completion :
    06/01/2019
    Completion :
    09/20/2020
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (CHALLENGE) (NCT03346811)
    Phase 2
    Betta Pharmaceuticals Co., Ltd.
    Unknown status
    Last update posted :
    11/17/2017
    Initiation :
    11/18/2017
    Primary completion :
    05/10/2019
    Completion :
    03/10/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC (NCT02714010)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    10/27/2017
    Initiation :
    08/01/2015
    Primary completion :
    12/01/2021
    Completion :
    12/01/2022
    EGFR
    |
    EGFR mutation
    |
    erlotinib • gefitinib • Conmana (icotinib)
    High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE) (NCT02404675)
    Phase 4
    Betta Pharmaceuticals Co., Ltd.
    Unknown status
    Last update posted :
    07/28/2017
    Initiation :
    04/01/2015
    Primary completion :
    12/01/2017
    Completion :
    09/01/2018
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    Conmana (icotinib)
    Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation (NCT03153358)
    Phase 2
    Sichuan Cancer Hospital and Research Institute
    Unknown status
    Last update posted :
    05/16/2017
    Initiation :
    06/02/2017
    Primary completion :
    11/02/2017
    Completion :
    05/02/2019
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (NCT01724801)
    Phase 3
    Guangdong Association of Clinical Trials
    Completed
    Last update posted :
    03/01/2017
    Initiation :
    10/14/2012
    Primary completion :
    06/30/2015
    Completion :
    09/14/2016
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma (NCT01665417)
    Phase 4
    Betta Pharmaceuticals Co., Ltd.
    Unknown status
    Last update posted :
    02/08/2017
    Initiation :
    08/01/2012
    Primary completion :
    07/01/2017
    Completion :
    12/01/2017
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • docetaxel • pemetrexed • Conmana (icotinib)
    Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR (NCT01744925)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Unknown status
    Last update posted :
    02/07/2017
    Initiation :
    10/01/2012
    Primary completion :
    11/01/2017
    Completion :
    12/01/2017
    EGFR
    |
    EGFR wild-type
    |
    Conmana (icotinib)
    Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy (NCT02787447)
    Phase 2
    First People's Hospital of Hangzhou
    Unknown status
    Last update posted :
    11/25/2016
    Initiation :
    05/01/2016
    Primary completion :
    12/01/2017
    Completion :
    05/01/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    erlotinib • gefitinib • Conmana (icotinib) • Zadaxin (thymalfasin)
    High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC (NCT02960607)
    Phase 2
    Chinese Academy of Medical Sciences
    Unknown status
    Last update posted :
    11/18/2016
    Initiation :
    11/01/2016
    Primary completion :
    01/01/2018
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation (NCT02961270)
    Phase 2
    Chinese Academy of Medical Sciences
    Unknown status
    Last update posted :
    11/11/2016
    Initiation :
    11/01/2016
    Primary completion :
    12/01/2017
    Completion :
    08/01/2018
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib)
    First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation (NCT02883543)
    Phase 3
    Daping Hospital and the Research Institute of S...
    Unknown status
    Last update posted :
    08/30/2016
    Initiation :
    06/01/2016
    Primary completion :
    06/01/2018
    Completion :
    06/01/2019
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    cisplatin • docetaxel • Conmana (icotinib)
    Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (NCT02882984)
    Phase 3
    Sichuan Provincial People's Hospital
    Unknown status
    Last update posted :
    08/30/2016
    Initiation :
    03/01/2015
    Primary completion :
    03/01/2020
    Completion :
    12/01/2020
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    erlotinib • gefitinib • Conmana (icotinib)
    Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma (NCT01745302)
    Phase N/A
    Shanghai University of Traditional Chinese Medi...
    Unknown status
    Last update posted :
    07/13/2016
    Initiation :
    11/01/2011
    Primary completion :
    12/01/2016
    Completion :
    12/01/2016
    EGFR
    |
    EGFR mutation
    |
    erlotinib • gefitinib • Conmana (icotinib)
    The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation (NCT02820116)
    Phase 2
    Beijing Haidian Hospital
    Recruiting
    Last update posted :
    06/30/2016
    Initiation :
    05/01/2016
    Primary completion :
    04/01/2023
    Completion :
    04/01/2023
    EGFR
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy (NCT02788058)
    Phase 2
    First People's Hospital of Hangzhou
    Unknown status
    Last update posted :
    06/02/2016
    Initiation :
    05/01/2016
    Primary completion :
    05/01/2021
    Completion :
    05/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    erlotinib • gefitinib • Conmana (icotinib)
    Conmana Combined With Thalidomide to Treat NSCLC (NCT02778893)
    Phase 4
    Henan Provincial People's Hospital
    Unknown status
    Last update posted :
    05/20/2016
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2017
    Completion :
    03/01/2020
    EGFR
    |
    EGFR mutation
    |
    Conmana (icotinib) • thalidomide
    Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (NCT02031601)
    Phase 4
    Qilu Hospital of Shandong University
    Unknown status
    Last update posted :
    03/29/2016
    Initiation :
    01/01/2014
    Primary completion :
    12/01/2016
    Completion :
    12/01/2017
    EGFR
    |
    EGFR mutation • EGFR positive • EGFR exon 18 mutation
    |
    cisplatin • erlotinib • carboplatin • gefitinib • docetaxel • pemetrexed • Conmana (icotinib)